2021 saw higher than ever funding of startups, continued maturation of the tech-enabled bio and healthcare landscape, and new platforms and business models that propelled growing levels of adoption and scale amongst both upstarts and traditional players. Accordingly, we nearly … The post New...

The RNA technology underlying both the Moderna and Pfizer/BioNTech vaccines could give us our fastest ticket out of the COVID-19 pandemic. With their rapid development and the early signs of success, RNA-based therapeutics are enjoying a well-deserved moment in the … The post The Second Coming of...

Virtually every company in biotech claims to have a platform. But historically, platforms weren’t particularly productive when it came to producing multiple new therapeutics. If successful therapeutics are the golden eggs of the biopharmaceutical industry, platforms are the geese, most … The...

In biotech, platforms — the combination of technology and scientific expertise — are the product engines that generate novel drug candidates. One important measure of a platform’s value is how many “shots on goal” — promising drug development programs — … The post Platform-Disease...